This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: CMO Co.
MPLN converting HPV Testing to Hologic/Gen-Probe APTIMA ASSAY.
Maryville, TN (PRWEB) December 06, 2012
MPLN announced today that they will be adopting the Hologic/Gen-Probe APTIMA Human papillomavirus (HPV) assay effective January 2, 2013. This assay will be run on the fully automated high throughput TIGRIS DTS System.
“Our goal at MPLN is to offer our clients the most comprehensive experience in molecular diagnostics, and we believe the new Hologic/Gen-Probe APTIMA HPV assay is a superior test to the method used in the past," said MPLN President and CEO Roger Hubbard, Ph.D. “Not only is there a significant number of performance benefits to the new test, the transition to this new technology should prove seamless for our clients. We believe that this new assay platform enhances our portfolio of testing in the area of women’s health.”
The APTIMA HPV assay detects 14 high-risk HPV types associated with cervical cancer and precancerous lesions. Testing is performed using ThinPrep™ liquid cytology specimens routinely used for Pap testing. Unlike other FDA-approved, DNA based HPV tests, the APTIMA HPV assay detects messenger RNA over-expressed from two viral oncogenes that are involved in the development of cervical cancer.
“We plan to offer a series of educational webinars beginning on January 16, 2013 for our current and prospective clients,” said Hubbard. “We are confident this new test will enhance the service we provide our clients and in turn improve patient care.” For more information about the APTIMA HPV test, contact an MPLN client service specialist at 800.932.2943 or visit http://www.mplnet.com.
About Molecular Pathology Laboratory Network
Located in Maryville, Tennessee, MPLN delivers an incomparable and unique client experience by delivering the most comprehensive services and innovative technologies in laboratory medicine. Providing an expanding menu of molecular diagnostics, specialty anatomic pathology, flow cytometry, and cytogenetic testing, MPLN is dedicated to providing superior diagnostic services to their clients in pathology groups, hospitals, medical laboratories and physician groups nationwide. MPLN specializes in oncology and women's health testing and excels by utilizing highly qualified physicians, innovative technologies, all backed by unparalleled service to meet diagnostic challenges in a timely, cost-effective manner.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10207487.htm